Four Bentham Science Journals indexed in The Emerging Sources Citation Index (ESCI)

The Emerging Sources Citation Index (ESCI), a new database within the Web of Science by Clarivate Analytics, has accepted to index four journals published by Bentham Science Publishers. The titles are:

The Emerging Sources Citation Index (ESCI) is a new index by Clarivate Analytics, extending the range of publications in Web of Science to include high-quality, peer-reviewed publications of regional importance and in emerging scientific fields. ESCI complements the highly selective indexes by providing earlier visibility for sources under evaluation as part of SCIE, SSCI, and AHCI’s rigorous journal selection process. Inclusion in ESCI provides greater discoverability which leads to increased citations.



The International Society for the Study of Xenobiotics (ISSX) signs agreement with Bentham Science Publishers to promote the journals, Current Drug Metabolism and Drug Metabolism Letters, among its members. ISSX is the premier scientific organization for researchers interested in the metabolism and disposition of xenobiotics.

Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of timely review articles and guest edited issues in drug metabolism. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism.

Drug Metabolism Letters publishes letters, original research articles, mini-reviews, thematic issues based on mini-reviews and letters, commentaries, technical notes and drug clinical trial studies on major advances in all areas of drug metabolism and disposition.



SMI EVENT – Adaptive Designs in Clinical Trials!

SMi is proud to present their Adaptive Designs in Clinical Trials conference on the 9th-10th of April 2018 in London, Uk.


Adaptive Designs in Clinical Trials 2018 will continue the discussion on recent developments and applications of state-of-the-art adaptive design techniques in clinical research. Experienced industry experts from across the globe will discuss recent real-life applications of group sequential and adaptive enrichment designs and give presentations on confirmatory designs with treatment selection and the use of basket, umbrella and platform studies in personalised medicine. Updates on the regulatory aspects and the evaluation of the use of new digital technologies in adaptive trials will also expand your knowledge of the current outlook in adaptive designs.

The full speaker line-up and conference agenda is available at 

For more information visit the website at or contact the team on email: or call +44 (0) 207 827 6012

Journal: Current Drug Delivery

EBook: Frontiers in Clinical Drug Research- Anti-Cancer Agents Volume 4

OPEN ACCESS ARTICLE – An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases – Current Respiratory Medicine Reviews

Journal: Current Respiratory Medicine Reviews


Graphical Abstract:



Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. In addition, new experimental evidence suggests that omalizumab may also interfere with the cellular and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering alternative mechanisms of modulating IgE pathway.

The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory diseases.

Read more here:


EDITOR’S CHOICE – Targeted Drug Delivery Systems and Their Therapeutic Applications in Cancer and Immune Pathological Conditions – Infectious Disorders – Drug Targets

Journal: Infectious Disorders – Drug Targets

Author(s): Jamshed Iqbal*, Fareeha Anwar, Saifullah Afridi*

Graphical Abstract:



Background: More than a century ago, Paul Ehrlich proposed the idea of a drug working as a “magic bullet” that selectively eliminates diseased cells without harming the surrounding normal cells. Since then, much progress has been made in this field to broaden the scope for targeted delivery of drugs. A major problem remain the toxic effects of targeted drugs on healthy cells. In order to reduce the adverse effects of chemotherapy on healthy tissues, we survey the use of recent drug delivery systems for targeted therapy.

Objective: The selective delivery of the drugs to specific diseased cells or tissues still is a daunting task. Ideally, for target drug delivery systems, the system should be made up of carriers and drugs, where carriers precisely target the desired drug. This issue covers the recent advancements in modern techniques for such purposes.

Result and Conclusion: It encompasses advances, benefits and limitations in state of art work of targeted drug delivery through hydrogels, microfluidics, nanoparticles, carbon nanotubes, polymeric micelles, liposomes, lipoprotein based drug carriers and dendrites.




Thought of the Day!


MOST ACCESSED ARTICLE – PEGylated Liposomes of Meloxicam – Pharmaceutical Nanotechnology

Journal: Pharmaceutical Nanotechnology

Author(s): Jessy Shaji*, Ipshita Menon

Graphical Abstract:



Background: Chemoprevention is a strategy which uses drugs which are traditionally not used as anti-cancer drugs; however, they prevent the carcinogenesis. Meloxicam (MLX) is traditionally used as a non-steroidal anti-inflammatory drug (NSAID), but it has been proven to have activity against colorectal cancer. Subsequently MLX seems to be a likely candidate to be utilized in the chemopreventive therapy of colorectal cancer. However, MLX poses shortcomings with respect to its dose required to elicit cytotoxicity. To improve the formulation, we used Quality by design (QbD) for optimization. QbD is a method that employs quality-improving scientific methods that build quality into the formulation by isolating the factors which affect the critical quality attributes of the formulation. The aim of the present study was to utilize the principles of QbD to formulate MLX into a formulation so as to exploit its potential to the fullest.

Methods: Conventional (CLM) and PEGylated liposomes (MPL) of MLX was prepared using hydrogenated soya phosphatidylcholine (HSPC), distearyl phosphatidyl glycerol (DSPG), cholesterol and 1, 2-distearoyl- phosphatidylethanolamine-methyl-polyethyleneglycol conjugate-2000 sodium salt (MPEG 2000 DSPE). The liposomes were prepared using thin film hydration method. The optimization of the formulation was done by employing the QbD approach. The formulation was optimized on the basis of the factors which were affecting the critical quality attributes (CQAs) such as particle size and entrapment efficiency. The final optimized formulation was characterized by assessing the particle size, percent entrapment efficiency, zeta potential, long-term stability, morphology, in vitro release and in vitro cytotoxic activity.

Result: PEGylated liposomes having high percent entrapment efficiency (87.25 %±0.72%) could be obtained. The entrapment of drug in the liposomes was confirmed using Differential Scanning Calorimetry (DSC), Fourier Transform Infrared spectroscopy (FT-IR) and Powder X-Ray diffraction (PXRD) studies. The mean particle size of the liposomes was 113 nm±67nm and they were found to exhibit sustained release profile (56.59 %±0. 43% drug in 24h). The Small Angle Neutron Scattering (SANS) analysis revealed that the liposomes were uniform sized LUVs (nm) and were spherical in shape. The shape of the liposomes was further confirmed by transmission electron microscopy (TEM). Long term stability study indicated that the formulation was stable for three months. Sulphorhodamine B (SRB) cytotoxicity assay was carried out in HT-29 cell to prove that the PEGylated liposomal formulations had higher cytotoxicity than the conventional liposomes after 48 hours of incubation.
Conclusion: The study affirmed that MLX loaded PEGylated liposomes had superior in vitro cytotoxicity as compared to the free drug as well as conventional liposomes. QbD resulted in the fabrication of a stable liposomal formulation with all the desirable characteristics. Hence, MLX loaded PEGylated liposomes can be considered to be a promising system for the delivery of MLX.

To access the article, please visit:

BENTHAM SCIENCE FREE TRIAL IN THE Institute of Advanced Study in Science and Technology (IASST), INDIA

The Institute of Advanced Study in Science & Technology (IASST) was set up in 1979 by the Assam Science Society with the prime objective of setting up a premier research establishment in the NE region to deal with problems of the north east in particular and the country in general. The Institute was inaugurated by the Nobel Laureate Prof. Dorothy Hodgkin on 3rd November 1979.

The Institute has been recently taken over as an autonomous research Institute by the Government of India under the Department of Science and Technology.

IASST has four basic divisions:

  • Material Sciences
  • Life Sciences
  • Resource Management and Environmental Sciences
  • Mathematical Sciences.